SecBot SecBot
8-K ·Filed Jul 31, 2026

VTGN

Vistagen Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001628280-26-051251
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Routine board appointment with no trading signal. Monitor for any future pipeline updates or financial disclosures, but this filing alone does not warrant a position change.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.2410
T+0 close · Jul 31, 2026 · via day close
Latest settled
−27.88%
T+60 · $0.1738
Vs SPY
−30.34%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 31 $0.2410entry
  2. T+1 · 4mo ago +1.66%α +0.24% · $0.2450
  3. T+5 · 3mo ago +19.34%α +15.82% · $0.2876
  4. T+20 · 3mo ago +4.94%α +1.95% · $0.2529
  5. T+60 · 22d ago −27.88%α −30.34% · $0.1738
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vistagen Therapeutics appointed Douglas J. Williamson, M.D. to its Board of Directors effective July 29, 2026. Dr. Williamson received stock options to purchase 40,826 shares at $0.2433 per share, vesting over three years. This is a routine board appointment with no material financial or operational impact.

Key Facts

  • Douglas J. Williamson, M.D. appointed to the Board of Directors on July 29, 2026.
  • Received options to purchase 40,826 shares of common stock at an exercise price of $0.2433 per share (closing price on appointment date).
  • Options vest in equal annual installments over three years, fully vested on the three-year anniversary.
  • Dr. Williamson also entitled to annual cash compensation and equity awards under the Director Compensation Plan.
  • Company entered into a standard Indemnification Agreement with Dr. Williamson.

Financial Impact

No material financial impact. The option grant is standard director compensation with a strike price at market.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-051251
Document: vtgn-20260729.htm0001628280-26-051251
Document: vtgn20260731ex991.htm0001628280-26-051251
Document: 0001628280-26-051251-index-headers.html0001628280-26-051251
Document: 0001628280-26-051251-index.html0001628280-26-051251
Document: 0001628280-26-051251.txt0001628280-26-051251

Track record

21 reports on VTGN

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
  2. Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
  3. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  5. Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
  6. Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
  7. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
  8. Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  9. Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  10. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
Showing 10 of 21

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 31, 2026